TB-500
Synthetic fragment corresponding to the active region of thymosin beta-4. Referenced in preclinical work on actin sequestration and tissue remodeling.
What the literature says.
Mechanism of action
Referenced mechanisms include G-actin sequestration, upregulation of metalloproteinases, and effects on cell migration relevant to wound-repair models.
Preclinical summary
TB-500 is a 17-amino-acid synthetic fragment modeling the actin-binding domain of thymosin beta-4. Preclinical literature covers cardiac, corneal, and soft-tissue remodeling models.
Safety
Research material only. Not a drug, supplement, or food product. No human or animal administration is supported or implied. Handling should follow the purchaser's institutional biosafety and chemical hygiene protocols.
Shipping & storage
Ships overnight in insulated packaging with ice packs when lab conditions require. Store lyophilized powder at 2–8°C. After reconstitution, store at 2–8°C and use within standard stability windows documented on the lot-specific Certificate of Analysis.
The compound, in numbers.
Research use only.
These products are intended for laboratory research purposes only and are not for human or animal consumption.
The statements on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
